JANX Janux Therapeutics (JANX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001817713
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
122
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $29.5K priced
What the filings say about JANX
Insiders, 180 days
-$85.8K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Janux Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Janux Therapeutics, Inc. insiders sold a net $85.8K of stock across 112 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.3% of the 75,941 shares held after it.
- 1 other insider sold within 30 days.
- 122 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel sold about $56.9K of JANX on Jun 2, 2026; 1 other insider sold within 30 days and 122 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 2, 2026.
- The trade is 6.3% of the 32,270 shares held after it.
- 1 other insider sold within 30 days.
- 122 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Vice President, Accounting Dobek Maria sold about $28.9K of JANX on May 11, 2026; 1 other insider sold within 30 days and 122 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Dec 1, 2025.
- The trade is 2.3% of the 83,095 shares held after it.
- 5 other insiders sold within 30 days.
- 122 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Meyer Andrew Hollman sold about $25.8K of JANX on Jan 2, 2026; 5 other insiders sold within 30 days and 122 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 27, 2024.
- The trade is 2.0% of the 124,425 shares held after it.
- 5 other insiders sold within 30 days.
- 122 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer DiRaimondo Thomas sold about $34.4K of JANX on Jan 2, 2026; 5 other insiders sold within 30 days and 122 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jan 7, 2025.
- The trade is 2.8% of the 284,982 shares held after it.
- 5 other insiders sold within 30 days.
- 122 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Campbell David Alan sold about $110.8K of JANX on Jan 2, 2026; 5 other insiders sold within 30 days and 122 funds added in the latest 13F quarter.112 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$85.8K over 180 days
more than 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
122 funds bought in last quarter
more than 76% of Pharma & Biotech
Revenue
-5.6% year over year
below 62% of Pharma & Biotech
Margin
-1136.3% net margin
below 87% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
13.4% of the float short (float per yahoo 2026-10-26) · 5.9 days to cover · settled 2026-09-30
more than 68% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch JANX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.8%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns JANX: institutional holders (13F)
13F holdings, latest reported quarter
11,189,693 sh
$171.9M
6,134,667 sh
$94.2M
3,804,481 sh
$58.4M
3,004,899 sh
$46.2M
2,412,825 sh
$37.1M
Congress trades in JANX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
JANX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
JANX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$1.9M position · as of 2026-07-31
1.0%
Federated Hermes MDT Small Cap Core Fund
$20.8M position · as of 2026-07-31
0.9%
Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund
$1.5M position · as of 2026-06-30
0.9%
Virtus Biotech Clinical Trials Etf
$347.7K position · as of 2026-07-31
0.7%
Federated Hermes MDT Small Cap Growth Fund
$5.7M position · as of 2026-07-31
0.7%
Tema Oncology ETF
$751.7K position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
4 active
1
Early Phase 1
1 active
What changed recently
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
2026-09-18 · Not Yet Recruiting → Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.5M
-$17.7M
$4.6M
+5%
+35%
2024
$9.0M
$55.2M
$5.0M
+307%
+2%
2023
$4.2M
$1.1M
$1.7M
-19%
+4%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $85.8K sold by insiders over 180 days, 122 funds added last quarter. Each figure is a federal filing, dated the day it went public.
JANX financials
Revenue growth
-5.6%
XBRL, annual
Net margin
-1136.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$24.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM JANX
| FY Dec 2025 | $10.0M |
| FY Dec 2024 | $10.6M |
| FY Dec 2023 | $8.1M |
| FY Dec 2022 | $8.6M |
| FY Dec 2021 | $3.6M |
| Jun 2026 | $10.3M |
| Mar 2026 | $3.7M |
| Dec 2025 | $0 |
| Sep 2025 | $10.0M |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $439.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-427.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM JANX
| FY Dec 2025 | -1,136% |
| FY Dec 2024 | -651.6% |
| FY Dec 2023 | -721.2% |
| FY Dec 2022 | -732.2% |
| FY Dec 2021 | -898.3% |
| Jun 2026 | -214.0% |
| Mar 2026 | -652.6% |
| Dec 2025 | n/a |
| Sep 2025 | -243.1% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -6,392% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$41.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM JANX
| FY Dec 2025 | -$83.3M |
| FY Dec 2024 | -$44.2M |
| FY Dec 2023 | -$52.4M |
| FY Dec 2022 | -$49.4M |
| FY Dec 2021 | -$18.5M |
| Jun 2026 | $12.3M |
| Mar 2026 | -$12.6M |
| Dec 2025 | -$28.6M |
| Sep 2025 | -$12.9M |
| Jun 2025 | -$24.3M |
| Mar 2025 | -$17.4M |
| Dec 2024 | -$16.8M |
| Sep 2024 | -$2.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity JANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt JANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity JANX
| FY Dec 2025 | -11.5% |
| FY Dec 2024 | -10.1% |
| FY Dec 2023 | -17.5% |
| FY Dec 2022 | -18.4% |
| FY Dec 2021 | -18.6% |
| Jun 2026 | -10.7% |
| Mar 2026 | -11.7% |
| Dec 2025 | -11.5% |
| Sep 2025 | -12.5% |
| Jun 2025 | -12.8% |
| Mar 2025 | -9.3% |
| Dec 2024 | -10.1% |
| Sep 2024 | -12.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-10.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets JANX
| FY Dec 2025 | -11.0% |
| FY Dec 2024 | -9.6% |
| FY Dec 2023 | -15.7% |
| FY Dec 2022 | -17.0% |
| FY Dec 2021 | -16.5% |
| Jun 2026 | -10.1% |
| Mar 2026 | -11.0% |
| Dec 2025 | -11.0% |
| Sep 2025 | -11.8% |
| Jun 2025 | -12.3% |
| Mar 2025 | -8.9% |
| Dec 2024 | -9.6% |
| Sep 2024 | -11.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital JANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-14.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed JANX
| FY Dec 2025 | -15.6% |
| FY Dec 2024 | -14.0% |
| FY Dec 2023 | -20.4% |
| FY Dec 2022 | -18.8% |
| FY Dec 2021 | -17.3% |
| Jun 2026 | -14.7% |
| Mar 2026 | -15.7% |
| Dec 2025 | -15.6% |
| Sep 2025 | -17.2% |
| Jun 2025 | -17.1% |
| Mar 2025 | -13.3% |
| Dec 2024 | -14.0% |
| Sep 2024 | -16.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing JANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value JANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield JANX
| FY Dec 2025 | -10.0% |
| FY Dec 2024 | -1.6% |
| FY Dec 2023 | -10.6% |
| FY Dec 2022 | -9.0% |
| FY Dec 2021 | -2.2% |
| Jun 2026 | -4.5% |
| Mar 2026 | -9.3% |
| Dec 2025 | -10.0% |
| Sep 2025 | -4.9% |
| Jun 2025 | -4.4% |
| Mar 2025 | -2.9% |
| Dec 2024 | -1.6% |
| Sep 2024 | -1.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing JANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M |
| EPS (diluted) | -1.83 | -1.28 | -1.32 | -1.52 |
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M |
| Cash | $52.3M | $430.6M | $19.2M | $51.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
JANX Stock Sonar score 5/7 axes
Find similar shapesCompareJANX ranks highest on profitability (76th percentile) and institutional and government (76th), and lowest on insider conviction (27th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
JANX filings, in plain words
Are Janux Therapeutics insiders buying or selling JANX?
In the 180 days to 2026-10-28, Janux Therapeutics insiders were net sellers, a net $85.8K across purchases and sales reported on Form 4, by 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Janux Therapeutics insiders were net sellers of JANX, a net $85.8K across purchases and sales reported on Form 4 by 2 sellers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
